Growth opportunity Emerging funding and strategic growth through recent Series B and acquisitions suggest readiness for expanded capabilities; target collaborations and integrative offerings with Fluxion Biosciences assets and new software for regulatory-compliant workflows to unlock larger multi-site deployments.

Regulatory push New software for the CellRaft AIR System emphasizing 21 CFR Part 11 compliance creates a sales angle for life science labs in regulated environments seeking validated, audit-ready single-cell workflow solutions.

Integrated systems Product portfolio spans cell engineering, 3D culture, and shear flow; cross-sell opportunities exist to labs needing end-to-end solutions from single cell isolation to organoid culture and automated patch-clamp-inspired tools.

Market momentum Recent launches and awards signal growing market validation; leverage competitive positioning by highlighting cost-effective Shear Flow Systems and advanced software to win mid-market researchers expanding to higher-throughput capabilities.

Strategic partnerships Presence in Durham with notable funding and leadership transition offers potential for regional collaborations, channel partnerships, and pilot programs with contract research organizations and academic labs adopting scalable single-cell workflows.